Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[A man with blisters on hand and feet].
Gelderblom AJ, van der Rhee JI, Ouwerkerk J. Gelderblom AJ, et al. Among authors: ouwerkerk j. Ned Tijdschr Geneeskd. 2011;155(45):A3994. Ned Tijdschr Geneeskd. 2011. PMID: 22085574 Dutch.
Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.
Steeghs N, Eskens FA, Gelderblom H, Verweij J, Nortier JW, Ouwerkerk J, van Noort C, Mariani M, Spinelli R, Carpinelli P, Laffranchi B, de Jonge MJ. Steeghs N, et al. Among authors: ouwerkerk j. J Clin Oncol. 2009 Oct 20;27(30):5094-101. doi: 10.1200/JCO.2008.21.6655. Epub 2009 Sep 21. J Clin Oncol. 2009. PMID: 19770380 Clinical Trial.
Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review.
Boers-Doets CB, Epstein JB, Raber-Durlacher JE, Ouwerkerk J, Logan RM, Brakenhoff JA, Lacouture ME, Gelderblom H. Boers-Doets CB, et al. Among authors: ouwerkerk j. Oncologist. 2012;17(1):135-44. doi: 10.1634/theoncologist.2011-0111. Epub 2011 Dec 29. Oncologist. 2012. PMID: 22207567 Free PMC article. Review.
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H. Eskens FA, et al. Among authors: ouwerkerk j. J Clin Oncol. 2009 Sep 1;27(25):4169-76. doi: 10.1200/JCO.2008.18.8193. Epub 2009 Jul 27. J Clin Oncol. 2009. PMID: 19636022 Clinical Trial.
Risk factors for catheter-related thrombosis in cancer patients.
Tesselaar ME, Ouwerkerk J, Nooy MA, Rosendaal FR, Osanto S. Tesselaar ME, et al. Among authors: ouwerkerk j. Eur J Cancer. 2004 Oct;40(15):2253-9. doi: 10.1016/j.ejca.2004.06.023. Eur J Cancer. 2004. PMID: 15454250 Free article.
66 results